Health Care Delivery

New research reveals disparities in opioid prescribing by race among Medicare beneficiaries, sparking concerns about potential impacts on rehabilitation outcomes.

During the presidential debate, former President Donald Trump and Vice President Kamala Harris shared their differing visions for the future of the Affordable Care Act (ACA).

During ESMO Congress 2024, sessions will focus on hot topics in therapeutic areas, such as antibody-drug conjugates; the latest trial data; health policy; and advances in technology.

The European approval comes months after the FDA’s approval of the first-of-its-kind treatment for pulmonary arterial hypertension (PAH).

Matthew Smeltzer, PhD, University of Memphis, shares insights into his team's quality-of-care initiative to identify and combat gaps in care for patients with early-stage non–small cell lung cancer (NSCLC).

A new report based on patient focus groups suggests many clinicians can do more to help patients with sickle cell disease (SCD) feel heard and understood.

Bellinda King-Kallimanis, PhD, LUNGevity Foundation, reflects on her experiences in patient-focused research to discuss the current state of patient education, the importance of patient advocates, and mediating barriers to health care access.

Ali Khawar, Employee Benefits Security Administration, US Department of Labor, believes the final rule will be a benefit to employers and health plans that are trying to do the right thing and offer robust mental health benefits or substance use benefits.

Patients who received radiotherapy without a recurrence of rectal cancer had significantly lower quality of life compared with patients who did not receive radiotherapy.

John Heymach, MD, PhD, The University of Texas MD Anderson Cancer Center, discusses exciting developments in HER2-targeted therapies that he foresees making a difference in the treatment of non–small cell lung cancer (NSCLC).

Ken Cohen, MD, of Optum Care, advocates for glucagon-like peptide 1 (GLP-1) tiering for patients with diabetes based on comorbidities, like body mass index (BMI) and cardiovascular disease (CVD).

Ana Baramidze, MD, PhD, Todua Clinic, Tbilisi, Georgia, details exciting findings from the EMPOWER-Lung 1 trial regarding cemiplimab and patients with non–small cell lung cancer (NSCLC).

Siow Ming Lee, PhD, FRCP, University College London Hospitals, discusses essential advancements necessary for improving immunotherapy outcomes in special patient subgroups with lung cancer.

Lung cancer screening experts from around the globe delivered strategies and best practices for improving access to screening and facilitating earlier detection at the 2024 World Conference on Lung Cancer.

The Center on Health Equity & Access provides the latest news, research, and expert opinions on the state of equity in health care.

The 2024 World Conference on Lung Cancer (WCLC), meeting in San Diego, California, from September 7 to 10, 2024, will feature practice-changing data and discussion in the lung cancer space.

If integrated into clinical practice, the approach could fill a need for more optimal diagnostic approaches for myasthenia gravis (MG), explained the researchers.

Lead investigators, presenters, and the chair of this year’s European Society of Cardiology Congress, John McMurray, MD, discussed the meeting highlights and recapped important data.

The tentative approval cannot take effect because a competing product was granted market exclusivity.

Recombinant Hirudin (rH) inhibited the polarization of M2-type macrophages and protease-activated receptor-1 (PAR-1) in diffuse large B-cell lymphoma (DLBCL).

This study characterized antihyperglycemic medication use after chronic kidney disease onset among patients with type 2 diabetes to uncover potential unmet needs in clinical practice.

Ian Neeland, MD, of University Hospitals and Case Western Reserve University, recommended a team-based, comprehensive approach to managing diabetes and its related complications.

According to some reports, the draft rule imposes strict limitations on telehealth prescriptions even as advocates push for extension of current flexibilities.

Manisha Jhamb, MD, MPH, of the University of Pittsburgh Medical Center (UPMC), is excited about CMS's negotiated drug prices under the Inflation Reduction Act (IRA) for patients with kidney disease; conversely, she highlights the challenge of low kidney disease awareness.

The authors assessed what attributes make provider networks adequate in the eyes of consumers, including travel times, inclusive care, and language access.

A recent study has found that higher serum levels of B-cell activating factor and anti-CCP3 are associated with a reduced risk of developing chronic lymphocytic leukemia (CLL), suggesting potential biomarkers for assessing CLL risk.

Ty J. Gluckman, MD, FACC, FAHA, of Providence St. Joseph Health, reacted positively to CMS' drug price cuts under the Inflation Reduction Act, but he also expressed concerns about the potential future impact on drug innovation.

A comparative analysis investigating time from a drug's approval to insurance reimbursement found that the speed of this process in the US falls behind some European countries.

New research linking telomere shortening to myelodysplastic syndromes (MDS) offers substantial therapeutic implications for affected patients and MDS research.

The COVID-19 pandemic accelerated the adoption of telehealth nationwide, revealing significant benefits while also exposing ongoing challenges.